Sareum Holdings PLC (GB:SAR)
LSE:SAR
Want to see GB:SAR full AI Analyst Report?
SAR Stock Chart & Stats
15.00 p
0.10 p(0.44%)
At close: 4:00 PM EST
15.00 p
0.10 p(0.44%)
Day’s Range― - ―
52-Week Range9.50 p - 29.00 p
Previous CloseN/A
Volume41.80K
Average Volume (3M)619.72K
Market Cap
£29.10M
Enterprise Value26.61M
Total Cash (Recent Filing)£2.49M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
Oct 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding138,565,170
10 Day Avg. Volume1,134,615
30 Day Avg. Volume619,716
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)8.68
Price to Sales (P/S)0.00
P/FCF Ratio-7.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£43.15M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet materially reduces fixed obligations and interest burden for an early-stage biotech. This structural financial flexibility lengthens runway options, eases deal negotiation with partners, and lowers bankruptcy risk, making the company more resilient across funding cycles.
Partnering/licensing Business ModelA model focused on licensing and partnerships aligns R&D risk with larger pharma partners and enables outsized upside from milestone and royalty streams without building commercial infrastructure. Structurally, this reduces fixed costs and leverages partner capabilities for late-stage development and sales.
Specialized Kinase R&D FocusPersistent scientific focus on TYK2/JAK kinase inhibition builds deep domain expertise and a coherent pipeline rationale. Over months this specialization can improve hit-to-lead efficiency, attract targeted partnerships, and create durable intellectual property advantages in a competitive therapeutic niche.
Bears Say
Pre-revenue And Persistent LossesBeing pre-revenue with recurring operating losses means the company lacks internally generated cash to fund development. Over the medium term this raises dilution risk from financing, limits reinvestment capacity, and keeps long-term viability contingent on successful partnerships or novel funding events.
Significant Cash Burn And Negative Free Cash FlowSustained negative operating and free cash flow forces dependence on external financing or licensing milestones. Structurally, continued burn narrows strategic options, pressures R&D timelines, and increases the chance of value-dilutive equity raises unless near-term deals or cost cuts restore positive cash dynamics.
Dependence On External Funding And Volatile EquityA small, fluctuating equity base and reliance on funding cycles make long-term planning vulnerable to capital market conditions. Structurally, this elevates execution risk for multi-year R&D projects, increases likelihood of partnership-driven timelines, and can compress negotiating power with potential licensors.
Sareum Holdings News
SAR FAQ
What was Sareum Holdings PLC’s price range in the past 12 months?
Sareum Holdings PLC lowest share price was 9.50 p and its highest was 29.00 p in the past 12 months.
What is Sareum Holdings PLC’s market cap?
Sareum Holdings PLC’s market cap is £29.10M.
When is Sareum Holdings PLC’s upcoming earnings report date?
Sareum Holdings PLC’s upcoming earnings report date is Oct 26, 2026 which is in 159 days.
How were Sareum Holdings PLC’s earnings last quarter?
Sareum Holdings PLC released its earnings results on Mar 12, 2026. The company reported -0.012 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.012 p.
Is Sareum Holdings PLC overvalued?
According to Wall Street analysts Sareum Holdings PLC’s price is currently Overvalued.
Does Sareum Holdings PLC pay dividends?
Sareum Holdings PLC does not currently pay dividends.
What is Sareum Holdings PLC’s EPS estimate?
Sareum Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sareum Holdings PLC have?
Sareum Holdings PLC has 138,565,170 shares outstanding.
What happened to Sareum Holdings PLC’s price movement after its last earnings report?
Sareum Holdings PLC reported an EPS of -0.012 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.143%.
Which hedge fund is a major shareholder of Sareum Holdings PLC?
Currently, no hedge funds are holding shares in GB:SAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sareum Holdings PLC
Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.
Technical Analysis
ImmuPharma
―
Fusion Antibodies Plc
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―